More than 200 people in nine states have reported bleeding or other symptoms associated with exposure to synthetic cannabinoid products containing an anticoagulant agent, including five who died, the Centers for Disease Control and Prevention reported Friday in an update on an outbreak that began in March. Most of the cases were in Illinois, and the rest in Maryland, Florida, Indiana, Kentucky, Missouri, Pennsylvania, Virginia and Wisconsin. Nearly all of the patients have tested positive for brodifacoum, a vitamin K antagonist anticoagulant, which public health officials believe may have been mixed with synthetic cannabinoid products, commonly referred to as synthetic marijuana, K2 or Spice. CDC said health care providers should screen patients presenting with unexplained bleeding and a possible history of synthetic cannabinoid for vitamin K-dependent antagonist coagulopathy, and report possible cases to their local health department, among other recommendations.

Related News Articles

Headline
The Administration for Strategic Preparedness and Response June 25 announced a flu pandemic preparedness and response strategy in response to the threat of…
Headline
A new report from the National Academies of Sciences, Engineering, and Medicine calls for developing better diagnostics, vaccines and treatments to enhance U.S…
Headline
AHA March 18 shared with the House Ways and Means Committee its proposals to strengthen access to timely emergency medical care, particularly in rural and…
Headline
The AHA and other founding members of the Common Health Coalition March 13 committed to action in four priority areas: coordination between health care and…
Headline
The AHA CLEAR Crisis Leadership Video Series, now available on demand, features hospital and health system leaders sharing insights, strategies and lessons…
Headline
Convening Leaders for Emergency and Response, AHA’s hub for emergency response and disaster preparedness resources, has released a “tip sheet” to help health…